Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 9;38(5):594-597.
doi: 10.1016/j.ccell.2020.10.006. Epub 2020 Oct 10.

COVID-19: Staging of a New Disease

Carlos Cordon-Cardo  1 , Elisabet Pujadas  2 , Ania Wajnberg  3 , Robert Sebra  4 , Gopi Patel  5 , Adolfo Firpo-Betancourt  2 , Mary Fowkes  2 , Emilia Sordillo  2 , Alberto Paniz-Mondolfi  2 , Jill Gregory  6 , Florian Krammer  7 , Viviana Simon  8 , Luis Isola  9 , Patrick Soon-Shiong  10 , Judith A Aberg  5 , Valentin Fuster  11 , David L Reich  12
Affiliations

COVID-19: Staging of a New Disease

Carlos Cordon-Cardo et al. Cancer Cell. .

Abstract

Coronavirus disease 2019 (COVID-19), like cancer, is a complex disease with clinical phases of progression. Initially conceptualized as a respiratory disease, COVID-19 is increasingly recognized as a multi-organ and heterogeneous illness. Disease staging is a method for measuring the progression and severity of an illness using objective clinical and molecular criteria. Integral to cancer staging is "metastasis," defined as the spread of a disease-producing agent, including neoplastic cells and pathogens such as certain viruses, from the primary site to distinct anatomic locations. Staging provides valuable frameworks and benchmarks for clinical decision-making in patient management, improved prognostication, and evidence-based treatment selection.

PubMed Disclaimer

Conflict of interest statement

Declaration of Interests C.C.-C., A.F.-B., F.K., and V.S., as part of Mount Sinai, report that the institution has licensed SARS-CoV-2 serological assays to commercial entities and have filed for patent protection for serological assays. R.S. reports to be associated with SEMA4. P.S.-S. is the chief executive officer and majority shareholder of both ImmunityBio, Inc., and NantKwest, Inc., and is developing a qLAMP assay.

Figures

Figure 1
Figure 1
COVID-19 Staging Visual summary of COVID-19 stages, with their associated pathophysiology, and suggested testing and therapeutic interventions. Illustration by Jill Gregory, used with permission of ©Mount Sinai Health System. ∗, approximate distribution of primary staging of disease among symptomatic patients.
See this image and copyright information in PMC

References

    1. Bryce C., Grimes Z., Pujadas E., Ahuja S., Beasley M.B., Albrecht R., Hernandez T., Stock A., Zhao Z., Al Rasheed M., et al. Pathophysiology of SARS-CoV-2: targeting of endothelial cells renders a complex disease with thrombotic microangiopathy and aberrant immune response. The Mount Sinai COVID-19 autopsy experience. medRxiv. 2020 doi: 10.1101/2020.05.18.20099960. - DOI
    1. Colafrancesco S., Alessandri C., Conti F., Priori R. COVID-19 gone bad: a new character in the spectrum of the hyperferritinemic syndrome? Autoimmun. Rev. 2020;19:102573. - PMC - PubMed
    1. Del Valle D.M., Kim-Schulze S., Huang H.H., Beckmann N.D., Nirenberg S., Wang B., Lavin Y., Swartz T.H., Madduri D., Stock A., et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med. 2020 doi: 10.1038/s41591-020-1051-9. Published online August 24, 2020. - DOI - PMC - PubMed
    1. Gandhi M., Yokoe D.S., Havlir D.V. Asymptomatic transmission, the Achilles’ heel of current strategies to control Covid-19. N. Engl. J. Med. 2020;382:2158–2160. - PMC - PubMed
    1. Golchin A., Seyedjafari E., Ardeshirylajimi A. Mesenchymal stem cell therapy for COVID-19: present or future. Stem Cell Rev. Rep. 2020;16:427–433. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources